Pharmacy Pearls for Prescribers- Migraine

Instructions to Receive Credit

Sunday, November 28, 2021, 8:00 AM - Saturday, December 31, 2022, 5:30 PM, Avera CE Portal

Pharmacy Pearls for Prescribers provides up-to-date information on medications, developed by a multidisciplinary group of AMG primary care physicians and pharmacists from Avera Health and Avera Health Insurance Division. An interdisciplinary group has been working to develop educational materials to meet this need. In this series we will discuss migraine management related to: acute treatment options, migraine prevention, and calcitonin gene-related peptide (CGRP) receptor antagonist medications.

Avera is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians. Avera designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit^TM per session.

Avera is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. A total 1.00 contact hours can be received upon completion of this activity.  This activity has been approved for 1.0 pharmacotherapeutic credits.

Avera Health Provider #1029 is an approved provider of continuing education by the South Dakota Board of Social Work Examiners.  Social Workers will receive 1.00  continuing education clock hours for participating in this course.

1. Describe acute treatments for migraines
2. Identify migraine prevention options
3. Discuss calcitonin genre-related peptide (CGRP) receptor antagonist medications

There is no cost for this educational activity.

 

© 2021 Avera Health, All Rights Reserved

 

 

Mitigation of Relevant Financial Relationships

Avera adheres to the Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control or influence the content of a CE activity, including but not limited to faculty, planners, authors, and reviewers are required to disclose all relevant financial relationships with an ineligible companies. All relevant financial relationships have been mitigated.